# Public-private partnerships are critical for rapid response to infectious disease threats

## TL;DR

Public-private partnerships are essential for quickly developing and scaling diagnostics during infectious disease outbreaks.

## Contribution

The paper highlights the role of public-private partnerships in enhancing diagnostic responses to infectious disease threats.

## Key findings

- Public-private partnerships have led to new test development and increased testing capacity.
- Collaboration between federal partners and manufacturers was critical during the COVID-19 and mpox responses.
- Establishing partnerships during non-crisis times enables faster action during outbreaks.

## Abstract

Public-private partnerships focused on infectious disease diagnostics have been increasing since the COVID-19 pandemic. These partnerships have resulted in new test development, increased testing capacity and services, technology development, and processes to enable faster collaborative response in the context of an outbreak. This paper explores the importance of public-private partnerships in response to infectious disease public health threats. Collaboration between federal partners and diagnostic test manufacturers has been critical to the COVID-19, mpox, and other responses in the United States, and these partnerships will be critical to future responses. Public-private partnerships pull together the pieces needed to rapidly develop and scale diagnostics necessary for responding to emerging infectious diseases. Developing partnerships during “peace time” further enables rapid action when outbreaks occur.